FindTrial
Sign In

RVU120

DRUG5 trials

Sponsors

Ryvu Therapeutics SA

Conditions

Acute Myeloid Leukaemia (AML)Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Advanced Solid TumorAdvanced Solid TumorsHigh-risk Myelodysplastic SyndromeMyelofibrosis

Phase 1

RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors
TerminatedNCT05052255
Ryvu Therapeutics SAAdvanced Solid Tumor
Start: 2021-08-13End: 2025-10-02Updated: 2026-09-18

Phase 2

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
RecruitingNCT06191263
Ryvu Therapeutics SAAcute Myeloid Leukemia
Start: 2024-01-05End: 2027-08-01Target: 98Updated: 2026-09-18
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
TerminatedNCT06268574
Ryvu Therapeutics SAAcute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome
Start: 2024-01-23End: 2025-09-05Updated: 2026-09-16
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
TerminatedNCT06397313
Ryvu Therapeutics SAMyelofibrosis
Start: 2024-09-19End: 2026-06-30Updated: 2026-09-16
RVU120 Rollover Study
Enrolling by invitationNCT06987058
Ryvu Therapeutics SAAcute Myeloid Leukaemia (AML), Advanced Solid Tumors, High-risk Myelodysplastic Syndrome
Start: 2025-12-04End: 2026-12-01Target: 14Updated: 2026-09-17

Related Papers

Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy
2025-12-18
An open-label, Phase I/II clinical trial of romaciclib (RVU120) as monotherapy and in combination with ruxolitinib in patients with intermediate or high-risk, primary or secondary myelofibrosis (POTAMI-61)
Blood2025-11-03
Preliminary results from RIVER-81, a phase 2 study of romaciclib (RVU120) + venetoclax in patients with acute myeloid leukemia failing first-line venetoclax + hypomethylating agent (HMA)
Blood2025-11-03
Trial in Progress: An Open-Label Clinical Trial of RVU120 As Monotherapy and in Combination with Ruxolitinib in Patients with Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)
Blood2024-11-051 citations
River-52: A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Blood2024-11-051 citations
Abstract 2647: RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells <i>in vitro</i> and <i>in vivo</i>
Cancer Research2022-06-15
Abstract CT131: RVU120 SOL-021: An open-label, single agent, phase I/II trial of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors
Cancer Research2022-06-15
Phase I/II trial of RVU120 (SEL120), a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors.
Journal of Clinical Oncology2022-06-017 citations